clinical trial · NCT06547528
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
Ono Pharmaceutical Co., Ltd.·phase1·recruiting·n = 108
Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaONO-4685
brief summary
A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL
started
Oct 1, 2023
primary completion
Jan 31, 2029
completion
Apr 30, 2029
last updated
Jun 3, 2025
official title
An Open-label, Uncontrolled, Phase I Dose Escalation Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol